Compare Jumia Technologies AG - ADR (JMIA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs State Street SPDR S&P Biotech ETF — how do they compare? Jumia Technologies AG - ADR trades at $5.98 (market cap $777.79M), while State Street SPDR S&P Biotech ETF trades at $152.24. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| JMIA | XBI | |
|---|---|---|
Market Cap | $777.79M | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $14.60 | $164.28 |
52-Week Low | $4.45 | $85.16 |
Enterprise Value | $724.89M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Jumia Technologies (JMIA) trades at $6.28, down 3.38% on the day, as the stock faces bearish technical pressure despite positive analyst sentiment. The company shows improving fundamentals with revenue growth to $188.93M in 2025 and narrowing losses, though it remains unprofitable with a -30.79% net margin. Recent Q1 2026 results showed 39% revenue growth and progress toward the 2027 profitability target, supported by strategic initiatives including upcountry expansion and the Starlink partnership.
While analyst consensus is strongly bullish (71% buy ratings), JMIA faces significant execution risks in achieving profitability amid African market challenges. The stock's current valuation at 3.86x sales appears reasonable for the growth trajectory, but persistent losses and high P/B ratio of 59.97 warrant caution. Near-term catalysts include continued GMV growth and margin improvement, but investors should monitor cash burn and competitive pressures.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
